Short Interest in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Expands By 26.1%

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) was the target of a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 161,600 shares, an increase of 26.1% from the August 15th total of 128,200 shares. Currently, 1.0% of the shares of the company are short sold. Based on an average daily volume of 76,500 shares, the short-interest ratio is currently 2.1 days.

Institutional Trading of Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Beaird Harris Wealth Management LLC raised its holdings in Telomir Pharmaceuticals by 212.9% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after purchasing an additional 9,950 shares during the period. Suncoast Equity Management bought a new position in shares of Telomir Pharmaceuticals in the first quarter worth about $126,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Telomir Pharmaceuticals during the 2nd quarter valued at about $241,000.

Telomir Pharmaceuticals Price Performance

TELO traded down $0.10 during mid-day trading on Monday, reaching $5.97. 7,422 shares of the company traded hands, compared to its average volume of 63,714. Telomir Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $20.72. The company’s fifty day moving average price is $4.57 and its 200-day moving average price is $5.68.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its earnings results on Tuesday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.